Davide Corti
Auto-generated profile, based on publicly available information

Davide Corti

Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2020 in Nature
Verified
Journal Article
Closed access
DPDora Pinto
Dora Pinto
YPYoung-Jun Park
Young-Jun Park
MBMartina Beltramello
Martina Beltramello
AWAlexandra C. Walls
Alexandra C. Walls
MTM. Alejandra Tortorici
M. Alejandra Tortorici
DCDavide Corti
Davide Corti

1 November 2020 in Cell
Verified
Journal Article
Closed access
LPLuca Piccoli
Luca Piccoli
YPYoung-Jun Park
Young-Jun Park
MTM. Alejandra Tortorici
M. Alejandra Tortorici
NCNadine Czudnochowski
Nadine Czudnochowski
AWAlexandra C. Walls
Alexandra C. Walls
DVDavid Veesler
David Veesler

23 December 2021 in Nature
Verified
Journal Article
Closed access
ECElisabetta Cameroni
Elisabetta Cameroni
JBJohn E. Bowen
John E. Bowen
LRLaura E. Rosen
Laura E. Rosen
CSChristian Saliba
Christian Saliba
SZSamantha K. Zepeda
Samantha K. Zepeda
DCDavide Corti
Davide Corti

1 April 2021 in Cell
Verified
Journal Article
Closed access
MMMatthew McCallum
Matthew McCallum
AMAnna De Marco
Anna De Marco
FLFlorian A. Lempp
Florian A. Lempp
MTM. Alejandra Tortorici
M. Alejandra Tortorici
DPDora Pinto
Dora Pinto
DVDavid Veesler
David Veesler

4 March 2021 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
RCRita E. Chen
Rita E. Chen
XZXianwen Zhang
Xianwen Zhang
JCJames Brett Case
James Brett Case
EWEmma S. Winkler
Emma S. Winkler
YLYang Liu
Yang Liu
MDMichael Diamond
Michael Diamond

19 August 2016 in Science
Verified
Journal Article
Closed access
PDF file
KSKarin Stettler
Karin Stettler
MBMartina Beltramello
Martina Beltramello
DEDiego A. Espinosa
Diego A. Espinosa
VGVictoria Graham
Victoria Graham
ACAntonino Cassotta
Antonino Cassotta
DCDavide Corti
Davide Corti
Characterizing the Zika virus antibody response: Given the public health emergency that Zika virus poses, scientists are seeking to understand the Zika-specific immune response. Stettler et al. analyzed 119 monoclonal antibodies isolated from four donors that were infected with Zika virus during the present epidemic, including two individuals that had previously been infected with dengue virus, another member of the flavivirus family. Neutralizing antibodies primarily recognized the envelope protein domain III (EDIII) or quaternary epitopes on the intact virus, and an EDIII-targeted antibody protected mice against lethal infection. Some EDI/II-targeting antibodies cross-reacted with dengue virus in vitro and could enhance disease in dengue-infected mice. Whether dengue and Zika virus antibodies cross-react in humans remains to be tested. Science , this issue p. 823